Sugi Predict

Sugi Predict / Compounds / SCHEMBL1443909

SCHEMBL1443909

SCHEMBL1443909

Fc1ccc(-c2cccc(CCl)c2-c2ccc(F)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP1 P22413 1/20 0.39
▸ PTGS2 P35354 6/20 0.36
▸ PTGS1 P23219 2/20 0.36
▸ ADORA2A P29274 2/20 0.35
▸ ADORA1 P30542 2/20 0.35
▸ DAPK3 O43293 1/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ PAK4 O96013 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ RET P07949 1/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ MET P08581 1/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ PRKACA P17612 1/20 0.35
▸ FLT1 P17948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9720771 0.89 TAAR1 (0.40) ADORA2AADORA1GSK3BCLK4
SCHEMBL9720776 0.89 TAAR1 (0.40) MAP4K4PRKACAGSK3BCLK4
SCHEMBL9720735 0.86 USP7 (0.34) ENPP1PTGS2PTGS1MAPK14HTR2C
SCHEMBL9720768 0.86 ALDH1A1 (0.36) ENPP1PTGS2PTGS1ADORA2AADORA1
SCHEMBL27487056 0.83 TTR (0.39) MAPK14POLBTYMPALDH1A1
SCHEMBL1443992 0.83 PDCD1 (0.43) ENPP1PTGS2PTGS1ADORA2AADORA1
SCHEMBL4429566 0.82 PTGS2 (0.43) PTGS2PTGS1MAPK14HTR2CSLC6A4
SCHEMBL27522250 0.82 DPP4 (0.47) ENPP1HTR7ALDH1A1TSHR
SCHEMBL8364039 0.80 NPC1 (0.38) PTGS2MAPK14POLBTYMPTSHR
SCHEMBL1443804 0.79 GRIA1 (0.39) ENPP1PTGS2PTGS1ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286389-B2 Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof Shenzhen Jingtai Technology Co., Ltd (CN) 2025-04-29 — — US disclosed
US-20220033347-A1 CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Jingtai Technology Co., Ltd (CN) 2022-02-03 — — US disclosed
WO-2020198939-A1 CRYSTALLINE FORM A OF 2,2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳仁泰医药科技有限公司 2020-10-08 — — WO disclosed
WO-2011034860-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2011-03-24 — — WO disclosed
US-20100056637-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2010-03-04 — — US disclosed
US-20090036538-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2009-02-05 — — US disclosed
EP-1968563-A2 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS Icagen, Inc. (US) 2008-09-17 — — EP disclosed
EP-1158971-B1 GARDOS CHANNEL ANTAGONISTS ICAGEN INC (US) 2007-08-22 — — EP disclosed
US-20070185209-A1 Treatment methods using triaryl methane compounds ICAGEN, INC. (US) 2007-08-09 — — US disclosed
WO-2007075849-A2 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS ICAGEN, INC. (US) 2007-07-05 — — WO disclosed
EP-1158971-A4 GARDOS CHANNEL ANTAGONISTS ICAGEN INC (US) 2003-04-16 — — EP disclosed
EP-1158971-A1 GARDOS CHANNEL ANTAGONISTS Icagen, Inc. (US) 2001-12-05 — — EP disclosed
US-6288122-B1 A TRIPHENYL ACETAMIDE ICAGEN, INC. 2001-09-11 — — US disclosed
WO-2000050026-A1 GARDOS CHANNEL ANTAGONISTS ICAGEN, INC. (US) 2000-08-31 — — WO disclosed
US-5149707-A 1-((2-FLUOROPHENYL)(4-FLUOROPHENYL)PHENYLMETHYL)-1H-IMIDAZOLE USEFUL AS ANTIFUNGAL AGENT J. URIACH & CIA, S.A. (ES) 1992-09-22 — — US disclosed
EP-0352352-B1 1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole J. URIACH & CIA. S.A. (ES) 1991-10-16 — — EP disclosed
EP-0352352-A1 1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole J. URIACH & CIA. S.A. (ES) 1990-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185209-A1 Treatment methods using triaryl methane compounds KCNH3, KCNH2, KCNJ2 ENPP1 3912/4885PTGS2 667/4885PTGS1 102/4885
US-20090036538-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS KCNH3, KCNH2, KCNJ2 ENPP1 3912/4885PTGS2 667/4885PTGS1 102/4885
US-12286389-B2 Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof WEE2, WEE1, WASF2 ENPP1 3934/4885PTGS2 730/4885PTGS1 908/4885
US-20220033347-A1 CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF WEE2, WEE1, WASF2 ENPP1 3934/4885PTGS2 730/4885PTGS1 908/4885
US-20100056637-A1 TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS LTC4S, LTB4R2, CYSLTR2 ENPP1 2447/4885PTGS2 33/4885PTGS1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.